Current Report Filing (8-k)
August 07 2017 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 7, 2017
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware
|
|
001-37526
|
|
26-0389433
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)
o
Precommencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
o
Precommencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 8.01 Other Events
On August 7, 2017, Zynerba Pharmaceuticals, Inc. issued a press release announcing top-line results from its double-blind placebo controlled Phase 2 STAR 1 (
S
ynthetic
T
ransdermal C
a
nnabidiol for the T
r
eatment of Epilepsy) clinical trial evaluating ZYN002 (cannabidiol gel) in adult epilepsy patients with focal seizures. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
|
|
Document
|
|
|
|
99.1
|
|
Press Release, dated August 7, 2017.
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 7, 2017
|
ZYNERBA PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Suzanne Hanlon
|
|
|
Name: Suzanne Hanlon
|
|
|
Title: Secretary, General Counsel and
Vice President, Human Resources
|
3
EXHIBIT INDEX
Exhibit
No.
|
|
Document
|
|
|
|
99.1
|
|
Press Release, dated August 7, 2017.
|
4
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Sep 2023 to Sep 2024